ITPNCT04890041
TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years
StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable Primary completion date: Nov 30, 2023 to Nov 30, 2025
- Study completion date: Dec 31, 2023 to Dec 31, 2025
Notable Enrollment target: 20 to 100v2 Show 7 more changesShow less
- Primary completion date: Nov 30, 2021 to Nov 30, 2023
- Eligibility criteria shortened, about 74 words
- Study completion date: Dec 31, 2021 to Dec 31, 2023
- Interventions: Avatrombopag (Drug) to TPO-RA (Drug)
- Secondary endpoints revised (5)
- Study description expanded, about 1 word
- Study title expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Treatment response
Timeframe: From the start of study treatment (Day 1) up to the end of week 6
Secondary (4)
Treatment response
Duration of response
Concomitant medication
Adverse events
Arms and interventions
Treatment groupExperimental
100 subjects will be enrolled with the indicated treatment dose of TPO-RA
Drugs: TPO-RA
Sites
1 site in 1 country
- Institute of Hematology & Blood Diseases HospitalTianjin, Tianjin Municipality, China